InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. James Craig, one of our Research Scientists at BayMedica.
James talks about enjoying the work at BayMedica for its broad scope from building and testing different cannabinoid strains to fermentation. James finds it rewarding to be part of a team that is working on cutting edge technology and researching a fairly untapped group of compounds (rare cannabinoids). Moreover, he believes the innovation can lead to developing compounds that can be beneficial and life-changing. James is excited to work with InMed and believes the synergies will help to accelerate and expand the manufacturing and development of rare cannabinoids at BayMedica.
James obtained his undergraduate degree in Cell and Molecular Biology Genetics from the University of Maryland and his PhD from the University of Maryland and conducted his postdoctoral studies at U.C. Berkeley.
